SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Arjan Boltjes, Marjoleine L. Op den Brouw, Paula J. Biesta, Rekha S. Binda, Renate G. van der Molen, Andre Boonstra, Harry L.A. Janssen, Andrea M. Woltman, Assessment of the effect of ribavirin on myeloid and plasmacytoid dendritic cells during interferon-based therapy of chronic hepatitis B patients, Molecular Immunology, 2013, 53, 1-2, 72

    CrossRef

  2. 2
    Margarita Pardo, Javier Bartolomé, Vicente Carreño, Current Therapy of Chronic Hepatitis B, Archives of Medical Research, 2007, 38, 6, 661

    CrossRef

  3. 3
    Chun-Jen Liu, Ming-Yang Lai, You-Chen Chao, Li-Ying Liao, Sien-Sing Yang, Tun-Jen Hsiao, Tsai-Yuan Hsieh, Chih-Lin Lin, Jui-Ting Hu, Chi-Ling Chen, Per-Jer Chen, Jia-Horng Kao, Ding-Shinn Chen, Interferon α-2b with and without ribavirin in the treatment of hepatitis B e antigen–positive chronic hepatitis B: A randomized study, Hepatology, 2006, 43, 4
  4. 4
    Yun-Fan Liaw, Nancy Leung, Richard Guan, George K.K. Lau, Ismail Merican, Geoff McCaughan, Edward Gane, Jia-Horng Kao, Masao Omata, Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update, Liver International, 2005, 25, 3
  5. 5
    CHAO-HUNG HUNG, CHUAN-MO LEE, SHENG-NAN LU, JING-HOUNG WANG, HUNG-DA TUNG, CHIEN-HUNG CHEN, CHI-SIN CHANGCHIEN, Combination therapy with interferon-α and ribavirin in patients with dual hepatitis B and hepatitis C virus infection, Journal of Gastroenterology and Hepatology, 2005, 20, 5
  6. 6
    Seong Soo Joo, Do Ik Lee, The potential anti-HBV effect of amantadine in combination with ursodeoxycholic acid and biphenyl dimethyl dicarboxylate in HepG2 2.2.15 cells, Archives of Pharmacal Research, 2005, 28, 4, 451

    CrossRef

  7. 7
    Chee-kin Hui, Hai-ying Zhang, George K.K. Lau, Management of chronic hepatitis B in treatment-experienced patients, Gastroenterology Clinics of North America, 2004, 33, 3, 601

    CrossRef

  8. 8
    Hari S Conjeevaram, Anna Suk-Fong Lok, Management of chronic hepatitis B, Journal of Hepatology, 2003, 38, 90

    CrossRef

  9. 9
    Raquel Muñoz, Gregorio Castellano, Inmaculada Fernández, Maria Victoria Álvarez, Maria Luisa Manzano, Maria Soledad Marcos, Beatriz Cuenca, José A Solı́s-Herruzo, A pilot study of β-interferon for treatment of patients with chronic hepatitis B who failed to respond to α-interferon, Journal of Hepatology, 2002, 37, 5, 655

    CrossRef

  10. 10
    ROBERT YM CHEN, PAUL V DESMOND, STEPHEN A LOCARNINI, Emerging therapies of hepatitis B and C, Journal of Gastroenterology and Hepatology, 2002, 17,
  11. 11
    SK SARIN, SK SATAPATHY, R CHAUHAN, Hepatitis B e-antigen negative chronic hepatitis B, Journal of Gastroenterology and Hepatology, 2002, 17,
  12. 12
    Vicente Carreño, Miguel A Rico, Margarita Pardo, Juan Antonio Quiroga, Extended follow-up of anti-HBe-positive patients with chronic hepatitis B retreated with ribavirin and interferon-α, Antiviral Research, 2001, 52, 2, 147

    CrossRef

  13. 13
    E. Herrero Martínez, Hepatitis B and hepatitis C co-infection in patients with HIV, Reviews in Medical Virology, 2001, 11, 4
  14. 14
    C.-C. Lin, J.-C. Wu, T.-T. Chang, Y.-H. Huang, Y.-J. Wang, S.-H. Tsay, N.-H. Chow, F.-Y. Chang, S.-D. Lee, Long-term evaluation of recombinant interferon α2b in the treatment of patients with hepatitis B e antigen-negative chronic hepatitis B in Taiwan, Journal of Viral Hepatitis, 2001, 8, 6
  15. 15
    Rafael Amaro, Eugene R. Schiff, Viral hepatitis, Current Opinion in Gastroenterology, 2001, 17, 3, 262

    CrossRef